Fundraising Fox

Third Arc Bio

Lower Gwynedd, US · Founded 2021 · Delaware corporation · 40 employees on LinkedIn · 12 known investors

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.

BiotechMedical Devices

Founders & leadership

JE
Joseph ErhardtExecutive
PL
Peter LebowitzExecutive

Board

AGArjun Goyal
Arjun Goyalin𝕏Board directorInvestment committee member at Tin Alley Ventures
OS
Otello StampacchiainBoard directorManaging Director at Omega Funds
FDFrancesco Draetta
Francesco DraettainBoard DirectorManaging Director at Omega Funds

Investors · 12

Andreessen HorowitzMenlo Park · $500K – $50M
Vida VenturesLos Angeles
abrdn plcreportedEdinburgh
Biotechnology Value FundreportedSan Francisco
Foresite CapitalreportedWest Hollywood
Hillhouse InvestmentreportedSingapore
Omega FundsreportedBoston
T. Rowe PricereportedBaltimore

Also in the syndicate · 4

AbbVie VenturesAlderline GroupGalapagos NVLife Sciences at Goldman Sachs Alternatives

Funding

SEC filings, press & company announcements

$124.5M disclosed across 2 rounds · 2024–2026

▶$72.5MraisedAug 2024 · 32 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph ErhardtExecutive Officer
  • Arjun GoyalDirector
  • Otello StampacchiaDirector
  • Peter LebowitzExecutive Officer, Director
  • Francesco DraettaDirector
Offering amount
$165M
Amount sold
$72.5M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
3T Biosciences11 shared keywords3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets. The company creates therapeutic treatments targeting cancer and other difficult-to-treat diseases.
3Bar Biologics10 shared keywords

Companies competing with Third Arc Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfoliofinance.yahoo.com · Feb 2026Montgomery County's Third Arc Bio raises another $52M led by top Silicon Valley VC firm - Philadelphia Business Journalbizjournals.com · Feb 2026Third Arc Bio raises USD 52m in Series A for multi-function antibodies - AllSciallsci.com · Feb 2026Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseasesprnewswire.com · Jul 2024

Frequently asked questions

What does Third Arc Bio do?
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.
Who are Third Arc Bio's investors?
Third Arc Bio's investors include Andreessen Horowitz, Vida Ventures, abrdn plc, Biotechnology Value Fund, Foresite Capital, Hillhouse Investment, Omega Funds, T. Rowe Price.
How much funding has Third Arc Bio raised?
Third Arc Bio has disclosed $124.5M raised across 2 rounds.
Where is Third Arc Bio headquartered?
Third Arc Bio is headquartered in Lower Gwynedd, US.